• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

重新审视用于治疗非复杂性恶性疟原虫疟疾的抗疟药物III期临床试验的设计。

Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria.

作者信息

Borrmann Steffen, Peto Tim, Snow Robert W, Gutteridge Win, White Nicholas J

机构信息

Steffen Borrmann is with the Kenya Medical Research Institute, Wellcome Trust Research Programme, Centre for Geographical Medicine Research, Coast, Kilifi, Kenya.

出版信息

PLoS Med. 2008 Nov 18;5(11):e227. doi: 10.1371/journal.pmed.0050227.

DOI:10.1371/journal.pmed.0050227
PMID:19018658
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2586344/
Abstract

Steffen Borrmann and colleagues discuss appropriate endpoints and their measurement during phase III trials of new antimalarial drugs.

摘要

斯特芬·博尔曼及其同事讨论了新型抗疟药物三期试验期间的适当终点及其测量方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e2f/2586344/c2d751d2842b/pmed.0050227.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e2f/2586344/8c2fb55eb059/pmed.0050227.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e2f/2586344/c2d751d2842b/pmed.0050227.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e2f/2586344/8c2fb55eb059/pmed.0050227.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e2f/2586344/c2d751d2842b/pmed.0050227.g002.jpg

相似文献

1
Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria.重新审视用于治疗非复杂性恶性疟原虫疟疾的抗疟药物III期临床试验的设计。
PLoS Med. 2008 Nov 18;5(11):e227. doi: 10.1371/journal.pmed.0050227.
2
Comparing highly efficacious antimalarial drugs.比较高效抗疟药物。
PLoS Med. 2008 Nov 18;5(11):e228. doi: 10.1371/journal.pmed.0050228.
3
The response of a case of multidrug-resistant, Plasmodium falciparum malaria to an unusual combination of antimalarial drugs.一例耐多药恶性疟原虫疟疾患者对抗疟药物异常组合的反应。
Ann Trop Med Parasitol. 2002 Jun;96(4):417-8. doi: 10.1179/000349802125001168.
4
The future outlook of antimalarial drugs and recent work on the treatment of malaria.抗疟药物的未来展望及疟疾治疗的近期研究进展
Arch Med Res. 2002 Jul-Aug;33(4):416-21. doi: 10.1016/s0188-4409(02)00371-5.
5
Helicases - feasible antimalarial drug target for Plasmodium falciparum.解旋酶——恶性疟原虫可行的抗疟药物靶点。
FEBS J. 2007 Sep;274(18):4699-704. doi: 10.1111/j.1742-4658.2007.06000.x.
6
Elucidating Mechanisms of Drug-Resistant Plasmodium falciparum.阐明耐药性疟原虫的作用机制。
Cell Host Microbe. 2019 Jul 10;26(1):35-47. doi: 10.1016/j.chom.2019.06.001.
7
Epidemiological distribution of Plasmodium falciparum drug resistance in Brazil and its relevance to the treatment and control of malaria.巴西恶性疟原虫耐药性的流行病学分布及其与疟疾治疗和控制的相关性。
Mem Inst Oswaldo Cruz. 1992;87 Suppl 3:343-8. doi: 10.1590/s0074-02761992000700058.
8
Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis.疟原虫感染后感染间日疟原虫的风险：系统评价和荟萃分析。
Lancet Infect Dis. 2019 Jan;19(1):91-101. doi: 10.1016/S1473-3099(18)30596-6.
9
Prevention and treatment of artemisinin-resistant falciparum malaria: update for international travellers.青蒿素耐药恶性疟的预防与治疗：国际旅行者最新指南
Wkly Epidemiol Rec. 2010 May 21;85(21):195-6.
10
Antimalarial drug resistance and mortality in falciparum malaria.恶性疟原虫疟疾中的抗疟药物耐药性与死亡率
Trop Med Int Health. 1999 Jul;4(7):469-70. doi: 10.1046/j.1365-3156.1999.00435.x.

引用本文的文献

1
Model-informed target product profiles of long-acting-injectables for use as seasonal malaria prevention.用作季节性疟疾预防的长效注射剂的模型指导目标产品概况。
PLOS Glob Public Health. 2022 Mar 14;2(3):e0000211. doi: 10.1371/journal.pgph.0000211. eCollection 2022.
2
Quinine plus clindamycin vs artemether-lumefantrine for treatment of uncomplicated falciparum malaria in western Kenya.在肯尼亚西部，奎宁加克林霉素与蒿甲醚-本芴醇治疗非复杂性恶性疟的对比研究
Malar J. 2022 Jun 21;21(1):198. doi: 10.1186/s12936-022-04222-6.
3
Optimal Duration of Follow-up for Assessing Antimalarial Efficacy in Pregnancy: A Retrospective Analysis of a Cohort Followed Up Until Delivery on the Thailand-Myanmar Border.

本文引用的文献

1
Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in children.恶性疟原虫种群大小和患者年龄对儿童抗疟治疗早期和晚期寄生虫学结果的影响。
Antimicrob Agents Chemother. 2008 May;52(5):1799-805. doi: 10.1128/AAC.00755-07. Epub 2008 Feb 25.
2
Risk associated with asymptomatic parasitaemia occurring post-antimalarial treatment.抗疟治疗后出现无症状寄生虫血症的相关风险。
Trop Med Int Health. 2008 Jan;13(1):83-90. doi: 10.1111/j.1365-3156.2007.01977.x.
3
Antimalarial dosing regimens and drug resistance.
评估孕期抗疟疗效的最佳随访时长：对泰国-缅甸边境地区一组随访至分娩的队列研究的回顾性分析
Open Forum Infect Dis. 2019 May 31;6(7):ofz264. doi: 10.1093/ofid/ofz264. eCollection 2019 Jul.
4
Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated Plasmodium falciparum malaria: pitfalls and challenges.统计方法推断抗疟药物治疗无并发症恶性疟原虫疟疾的疗效：陷阱和挑战。
Malar J. 2017 Oct 26;16(1):430. doi: 10.1186/s12936-017-2074-7.
5
Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast.肯尼亚沿海地区恶性疟原虫感染对青蒿素为基础的联合疗法的反应性下降。
PLoS One. 2011;6(11):e26005. doi: 10.1371/journal.pone.0026005. Epub 2011 Nov 10.
6
The perils of PCR: can we accurately 'correct' antimalarial trials?PCR 的风险：我们能准确“纠正”抗疟试验吗？
Trends Parasitol. 2010 Mar;26(3):119-24. doi: 10.1016/j.pt.2009.12.007. Epub 2010 Jan 18.
7
The effect of varying analytical methods on estimates of anti-malarial clinical efficacy.不同分析方法对抗疟疾临床疗效评估的影响。
Malar J. 2009 Apr 22;8:77. doi: 10.1186/1475-2875-8-77.
8
Comparing highly efficacious antimalarial drugs.比较高效抗疟药物。
PLoS Med. 2008 Nov 18;5(11):e228. doi: 10.1371/journal.pmed.0050228.
抗疟药物给药方案与耐药性。
Trends Parasitol. 2008 Mar;24(3):127-34. doi: 10.1016/j.pt.2007.11.008. Epub 2008 Feb 11.
4
How antimalarial drug resistance affects post-treatment prophylaxis.抗疟药耐药性如何影响治疗后预防措施。
Malar J. 2008 Jan 11;7:9. doi: 10.1186/1475-2875-7-9.
5
Can estimates of antimalarial efficacy from field studies be improved?来自现场研究的抗疟疗效估计值能否得到改进？
Trends Parasitol. 2008 Feb;24(2):68-73. doi: 10.1016/j.pt.2007.11.003. Epub 2008 Jan 7.
6
Monitoring and deterring drug-resistant malaria in the era of combination therapy.联合治疗时代耐药性疟疾的监测与遏制
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):160-9.
7
Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar.以青蒿素为基础的联合疗法和经杀虫剂处理的蚊帐对桑给巴尔疟疾负担的影响。
PLoS Med. 2007 Nov 6;4(11):e309. doi: 10.1371/journal.pmed.0040309.
8
Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria.双氢青蒿素-哌喹治疗耐药疟疾的治疗反应的临床和药理学决定因素。
Antimicrob Agents Chemother. 2007 Nov;51(11):4090-7. doi: 10.1128/AAC.00486-07. Epub 2007 Sep 10.
9
World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs.世界抗疟药物耐药性网络I：抗疟药物的临床疗效。
Malar J. 2007 Sep 6;6:119. doi: 10.1186/1475-2875-6-119.
10
Efficacy studies of malaria treatments in Africa: efficient estimation with missing indicators of failure.非洲疟疾治疗的疗效研究：利用失败的缺失指标进行有效估计。
Stat Methods Med Res. 2008 Apr;17(2):191-206. doi: 10.1177/0962280207078202. Epub 2007 Aug 14.